DrugPatentWatch Database Preview

Am Regent Company Profile

« Back to Dashboard

What is the competitive landscape for AM REGENT, and what generic alternatives to AM REGENT drugs are available?

AM REGENT has thirty-four approved drugs.

There are four US patents protecting AM REGENT drugs.

There are sixty-one patent family members on AM REGENT drugs in thirty-two countries and seventy-eight supplementary protection certificates in twelve countries.

Summary for Am Regent

International Patents:	61
US Patents:	4
Tradenames:	32
Ingredients:	30
NDAs:	34

Drugs and US Patents for Am Regent

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	METHOCARBAMOL	methocarbamol	SOLUTION;IM-IV	207496-001	Jun 22, 2017	AP	RX	No	No
Am Regent	INJECTAFER	ferric carboxymaltose	INJECTABLE;INTRAVENOUS	203565-001	Jul 25, 2013		RX	Yes	Yes	7,612,109		Y	Y
Am Regent	NEOSTIGMINE METHYLSULFATE	neostigmine methylsulfate	SOLUTION;INTRAVENOUS	209182-001	May 4, 2018	AP	RX	No	No
Am Regent	TESTOSTERONE CYPIONATE	testosterone cypionate	INJECTABLE;INJECTION	207742-001	Jun 16, 2017	AO	RX	No	No
Am Regent	EPINEPHRINE	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	207568-001	Jul 6, 2018		DISCN	No	No
Am Regent	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	INJECTABLE;INJECTION	070826-001	Feb 11, 1987		DISCN	No	No
Am Regent	DICYCLOMINE HYDROCHLORIDE	dicyclomine hydrochloride	INJECTABLE;INJECTION	208353-001	Feb 17, 2017	AP	RX	No	No

International Patents for Am Regent Drugs

Country	Patent Number	Estimated Expiration
South Korea	20170028449
Slovenia	2287204
Taiwan	200420289
Slovenia	1554315
Taiwan	I265028
Norway	20110654
South Africa	200504174

Supplementary Protection Certificates for Am Regent Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435025	2019C/532	Belgium		PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
0933372	13/2008	Austria		PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0398460	12/2004	Austria		PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
0933372	SPC/GB08/018	United Kingdom		PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
2365988	CA 2018 00006	Denmark		PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Am Regent